This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CRN discounts conclusions of omega-3 meta-analysis

&nbsp;
CRN says consumers should not be swayed by the study&#39;s results and that omega-3 supplements are an affordable, convenient and safe way to obtain the health benefits of omega-3 fatty acids.

Council for Responsible Nutrition | Sep 11, 2012

In response to a meta-analysis titled “Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events” published online Sept. 11 in the Journal of the American Medical Association, the Council for Responsible Nutrition (CRN), the leading trade association representing the dietary supplement industry, issued the following statement:

Statement by Duffy MacKay, N.D., vice president, scientific and regulatory affairs, CRN: “Consumers should not discount the many proven benefits of omega-3 fatty acids in all stages of life. There is extensive scientific evidence demonstrating the importance of omega-3 fats during pregnancy/lactation, breastfeeding and childhood. Furthermore, omega-3 fats have a role in maintaining the health of adults as well as in the prevention of age-related chronic diseases (e.g., cardiovascular disease and cognitive decline). This study does not change the current recommendations by authoritative bodies such as the World Health Organization, American Heart Association and the U.S. National Academies of Science, who recommend adequate consumption of omega-3 fats.

Our main concern is that the results of this meta-analysis will be taken out of context. The attraction of doing a meta-analysis is to combine comparable smaller clinical studies to assess whether similarities in the combined results exist. The problem is that this meta-analysis combined studies that were not comparable in their design (e.g., studies on healthy individuals were combined with those targeting diseased individuals), which makes the results more skew. Second, omega-3 fatty acids are vital nutrients and not drugs. Many of the studies included in the meta-analysis were conducted on diseased individuals already undergoing treatment with one or more drugs (e.g., statins), which may mask the less potent and more long-term effects of omega-3 fats. Along these lines, the researchers apparently did not examine within each individual study included in the meta-analysis whether individuals in the placebo group were sufficient or insufficient in their dietary intake omega-3 fats. Without that information, they could not have controlled for this variable. In this regard, studies on drugs are far simpler than those of nutrients (the treatment group gets the drug and the placebo group does not); with nutrients, if participants in the control group already have a diet sufficient in that substance, then it will be that much harder to demonstrate any benefit among the treatment participants. It is impossible for five researchers to control the diet of almost 70,000 patients over several years (particularly as a retrospective meta-analysis), as omega-3 fats are widespread throughout a variety of foods.

In conclusion, consumers should not be swayed by these results. While people should be eating a diet high in fatty fish which contain these nutrients, the reality is that people are simply not doing this. Omega-3 supplements serve as an affordable, convenient and safe way to obtain omega-3 fatty acids and the array of health benefits they offer.”